Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
Hepatology Research2023Vol. 53(5), pp. 383–390
Citations Over TimeTop 1% of 2023 papers
Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita, Takeyuki Watadani, Masaki Kaibori, Shoji Kubo, Mitsuo Shimada, Hiroaki Nagano, Etsuro Hatano, Hiroshi Aikata, Hiroko Iijima, Kazuomi Ueshima, Kazuyoshi Ohkawa, Takuya Genda, Kaoru Tsuchiya, Takuji Torimura, Masafumi Ikeda, Junji Furuse, Masaaki Akahane, Satoshi Kobayashi, Hideyuki Sakurai, Atsuya Takeda, Takamichi Murakami, Utaroh Motosugi, Yutaka Matsuyama, Masatoshi Kudo, Ryosuke Tateishi
Abstract
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance-diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described.
Related Papers
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.(2003)
- Pathology of hepatocellular carcinoma(2006)
- → Hepatology and Transplant Hepatology(2010)2 cited
- → HEPATOLOGY and hepatology: The good, the bad, and the ugly(1996)
- → P0320 AUTOIMMUNE HEPATITIS: MULTICENTRE DATA AT DIAGNOSIS IN 245 CHILDREN(2004)